GlassScriptPhysician profile
William A Newman
NPI 1114995214
$4,172.37
in general payments reported to CMS, 2019-2025
40 companies · $650 in 2025
The $650 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $236 · 2021: $140 · 2022: $979 · 2023: $749 · 2024: $551 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $582.65 | 2023-2025 | Tymlos |
| Abbvie INC. | $487.79 | 2019-2025 | |
| Hologic Sales and Service, LLC | $445.32 | 2019-2025 | Aptima |
| Astellas Pharma US INC | $370.47 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $242.08 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $186.41 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $181.60 | 2023-2025 | Myfembree, Gemtesa |
| Therapeuticsmd, INC. | $165.92 | 2019-2022 | |
| Scynexis, INC. | $156.79 | 2022 | |
| Sage Therapeutics, LLC | $124.75 | 2023-2025 | Zurzuvae |
| Pfizer INC. | $121.93 | 2019-2025 | |
| Medical Device Business Services, INC. | $102.99 | 2021 | |
| Channel Medsystems, INC. | $96.61 | 2024 | |
| Myovant Sciences INC. | $87.14 | 2022 | |
| Coopersurgical, INC. | $85.16 | 2019-2024 | Paragard T 380a, Paragard T 380a |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.